EyePoint Pharmaceuticals, Inc. – EYPT

EyePoint Pharmaceuticals, Inc. is a small cap company that is in the business of developing eye products via a ‘long-term, sustained release delivery’ platform. Their current products that have been developed, tested, and are ready for the market is DEXYCU and YUTIQ. Although not yet approved by the FDA, Yutiq I suspect will get the green light. Now, from digging through releases and listening to conference calls, it is very clear that the company is gearing up for commercialization of these products. Management, it seems, is visibly executing on that strategy with the clear goal of commercialization which is why I’ve taken a liking to the prospects presented here and started a position. As there are roughly 4 million eye operations per year for which Dexycu and Yutiq can provide post operative relief, I’m betting it’s only a matter of time before EYPT could expect to achieve positive cash flow following successful commercialization efforts.

It’s taken a little time for things to develop favorably for shareholders of EyePoint Pharmaceuticals and there’s still some time to go. However, if you can hold a position for a few months, I believe this small cap should become another 100% or more share price growth candidate. Navigate to the Position Details page to see more stock information.